Putting the award page together from the records…
Putting the award page together from the records…
CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
119 subawards totaling $82.61M (65.7% of what was obligated), as Trustees of Boston University reported them. Primes report subawards of $30,000 or more; smaller ones and unreported ones aren't here.
| Subcontractor | Amount | Subawards | Where | First | Last |
|---|---|---|---|---|---|
| Limmatech Biologics Ag | $11.14M | 2 | ZH | 2023-12-21 | 2024-03-12 |
| Day Zero Diagnostics Inc | $9.08M | 5 | MA | 2022-10-20 | 2025-02-11 |
| Basilea Pharmaceutica Ag | $9.05M | 1 | 2024-04-04 | 2024-04-04 | |
| Genomic Labs LTD | $5.43M | 1 | 2022-11-02 | 2022-11-02 | |
| Snipr Biome Aps | $3.95M | 1 | 2022-11-15 | 2022-11-15 | |
| Vedanta Biosciences, Inc. | $2.60M | 1 | MA | 2022-12-09 | 2022-12-09 |
| Peptilogics Inc | $2.48M | 3 | PA | 2022-10-06 | 2024-12-06 |
| Viiv Healthcare Company | $2.47M | 2 | 2023-02-09 | 2023-02-09 | |
| Visby Medical, Inc. | $2.45M | 1 | CA | 2023-12-07 | 2023-12-07 |
| Vaxdyn Sociedad Limitada | $2.04M | 1 | 2023-01-23 | 2023-01-23 | |
| Debiopharm International Sa | $1.95M | 1 | VD | 2022-10-06 | 2022-10-06 |
| Centauri Therapeutics Limited | $1.81M | 1 | 2025-04-17 | 2025-04-17 | |
| Uh-Oh Labs Inc | $1.49M | 4 | CA | 2024-03-26 | 2025-10-22 |
| Mutabilis | $1.49M | 1 | 2022-12-19 | 2022-12-19 | |
| Meliolabs Inc | $1.44M | 1 | CA | 2024-12-19 | 2024-12-19 |
| President and Fellows of Harvard College | $1.28M | 3 | MA | 2024-01-19 | 2026-02-25 |
| Macro Biologics, Inc. | $1.24M | 1 | CA | 2022-11-07 | 2022-11-07 |
| Helmholtz-Zentrum Fuer Infektionsforschung GMBH | $1.19M | 7 | 2022-12-08 | 2025-02-28 | |
| Institute for Life Science Entrepreneurship Inc | $1.07M | 1 | NJ | 2023-01-24 | 2023-01-24 |
| Lumen Bioscience, Inc | $1.07M | 1 | WA | 2022-10-05 | 2022-10-05 |
| Avails Medical, Inc | $1.04M | 3 | CA | 2023-04-26 | 2023-12-14 |
| Arrepath Inc | $1.03M | 1 | NJ | 2025-03-25 | 2025-03-25 |
| Chembio Diagnostic Systems Inc. | $1.01M | 1 | NY | 2026-02-03 | 2026-02-03 |
| Quantamatrix Incorporated | $998.1K | 1 | 2025-08-18 | 2025-08-18 | |
| Seres Therapeutics, Inc. | $895.7K | 1 | MA | 2025-09-15 | 2025-09-15 |
The 25 largest of 75; the rest are on USAspending.gov.
| Date | To | Amount | For |
|---|---|---|---|
| 2024-04-04 | Basilea Pharmaceutica International LTD, Allschwil | $9.05M | INFECTIONS CAUSED BY MULTIDRUG-RESISTANT BACTERIA HAVE BECOME ONE OF THE MOST IMPORTANT THREATS TO GLOBAL HEALTH, RESULTING IN AN ESTIMATED 1.27 MILLION GLOBAL DEATHS IN 2019. GRAM-NEGATIVE BACTERIA ARE OF PARTICULAR… |
| 2023-12-21 | Limmatech Biologics Ag | $7.97M | THE CONCURRENT RISE OF ANTIMICROBIAL RESISTANCE AND INCIDENCE OF SEXUALLY TRANSMITTED INFECTIONS IS A WORRYING COMBINATION. IN THE PAST DECADE, CASES OF GONORRHEA HAVE MORE THAN DOUBLED IN MANY COUNTRIES – IN THE US… |
| 2022-10-20 | Day Zero Diagnostics Inc | $7.84M | DAY ZERO DIAGNOSTICS IS DEVELOPING A CULTURE-FREE, SEQUENCING-BASED DIAGNOSTIC THAT IDENTIFIES WITHIN HOURS BOTH THE SPECIES AND THE ANTIBIOTIC RESISTANCE PROFILE OF A BACTERIAL INFECTION. WE HAVE DEVELOPED AN… |
| 2022-11-02 | Genomic Labs LTD | $5.43M | CURRENT CLINICAL DIAGNOSTICS FOR INFECTIONS, SUCH AS SEPSIS, ARE FUNDAMENTALLY LIMITED BY HAVING TO GROW BACTERIA. DUE TO THIS, IT TAKES 24-72 HOURS TO DETERMINE WHICH ANTIBIOTICS WILL EFFECTIVELY TREAT SEPSIS, AND THE… |
| 2022-11-15 | Snipr Biome Aps | $3.95M | PRECISION KILLING OF BACTERIA HAS THE IMPACT TO REVOLUTIONIZE THE MANAGEMENT OF UNTREATABLE AND DIFFICULT-TO-TREAT INFECTIONS INCLUDING ANTI-MICROBIAL RESISTANT STRAINS, AS WELL AS COMPLEX DISEASES DIRECTLY IMPACTED BY… |
| 2024-03-12 | Limmatech Biologics Ag | $3.17M | STAPHYLOCOCCUS AUREUS (SA), CAUSES SERIOUS DISEASES INCLUDING BLOOD STREAM INFECTION, SEPSIS, ENDOCARDITIS, SURGICAL SITE INFECTIONS (SSI), AND PNEUMONIA. METHICILLIN RESISTANT SA (MRSA) IS CURRENTLY A LEADING CAUSE OF… |
| 2022-12-09 | Vedanta Biosciences, Inc. | $2.60M | ANTIBIOTIC RESISTANCE IS A GROWING PUBLIC HEALTH CONCERN WORSENED BY THE LACK OF EFFECTIVE ANTIMICROBIAL THERAPIES TO TREAT INFECTIONS WITH MULTIDRUG-RESISTANT ORGANISMS (MDRO). OF THESE, CARBAPENEM-RESISTANT… |
| 2023-12-07 | Visby Medical, Inc. | $2.45M | VISBY MEDICAL IS THE MAKER OF AN INNOVATIVE INSTRUMENT-FREE, SINGLE USE PCR PLATFORM FOR THE DETECTION OF INFECTIOUS DISEASES. THEIR SEXUAL HEALTH TEST DETECTS CHLAMYDIA, GONORRHEA, AND TRICHOMONAS WITH ~97% ACCURACY… |
| 2023-02-09 | Glaxosmithkline Biologicals | $2.31M | STREP A IS A GRAM-POSITIVE BACTERIUM WITH A RICH REPERTOIRE OF VIRULENCE FACTORS THAT ALLOWS FOR A WIDE SPECTRUM OF CLINICAL MANIFESTATIONS. STREP A IS THE COMMON CAUSE OF BACTERIAL SORE THROATS (PHARYNGITIS) AND SKIN… |
| 2023-01-23 | Vaxdyn Sociedad Limitada | $2.04M | THE SPANISH BIOTECHNOLOGY COMPANY VAXDYN HAS DEVELOPED PROPRIETARY TECHNOLOGY ENABLING THE EXPRESSION AND PRESENTATION OF HETEROLOGOUS ANTIGENS ON THE SURFACE OF DETOXIFIED BACTERIAL CELLS. THIS TECHNOLOGY FACILITATES… |
| 2022-10-06 | Debiopharm International Sa | $1.95M | DEBIOPHARM IS DEVELOPING DEBIO 1453, A CLINICAL DEVELOPMENT CANDIDATE, BELONGING TO A NEW CLASS OF ANTIBIOTICS, HAVING A NOVEL MECHANISM OF ACTION, AND WITH ACTIVITY AGAINST NEISSERIA GONORRHOEAE, THE CAUSATIVE… |
| 2023-04-26 | Avails Medical, Inc | $1.81M | AVAILS MEDICAL, INC. IS AN IN VITRO DIAGNOSTICS COMPANY DEDICATED TO PROVIDING SOLUTIONS FOR THE GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE AND HEALTHCARE ASSOCIATED INFECTIONS, BEGINNING WITH THE BACTEREMIA DIAGNOSTICS… |
| 2025-04-17 | Centauri Therapeutics Limited | $1.81M | CENTAURI IS A PRIVATELY-OWNED BIOTECH COMPANY DEVELOPING NOVEL IMMUNOTHERAPEUTICS TO TREAT LIFE-THREATENING DISEASES. CENTAURI HAS A DEVELOPED AN IMMUNOTHERAPEUTIC PLATFORM (ALPHAMERS) THAT REDIRECTS PRE-EXISTING… |
| 2024-12-06 | Peptilogics Inc | $1.52M | PEPTILOGICS IS A BIOTECHNOLOGY COMPANY THAT UTILIZES AN INNOVATIVE PLATFORM TO DEVELOP NOVEL PEPTIDE THERAPEUTICS TO ADDRESS UNMET MEDICAL NEEDS. OUR PIPELINE INCLUDES A NOVEL CLASS OF ENGINEERED CATIONIC ANTIBIOTIC… |
| 2025-02-11 | Day Zero Diagnostics Inc | $1.50M | DAY ZERO DIAGNOSTICS IS DEVELOPING A CULTURE-FREE, SEQUENCING-BASED DIAGNOSTIC THAT IDENTIFIES WITHIN HOURS BOTH THE SPECIES AND THE ANTIBIOTIC RESISTANCE PROFILE OF A BACTERIAL INFECTION. WE HAVE DEVELOPED AN… |
| 2022-12-19 | Mutabilis | $1.49M | BETA-LACTAMS ARE SAFE, HIGHLY POTENT AND THE MOST WIDELY USED ANTIBACTERIALS CLASS. THEIR OVERWHELMING SUCCESS HAS LED TO HIGH VOLUME USE AND OFTEN MISUSE/OVERUSE. WIDESPREAD RESISTANCE IS NOW A REALITY ESPECIALLY IN… |
| 2024-12-19 | Meliolabs Inc. | $1.44M | MELIO IS COMMITTED TO REVOLUTIONIZING THE HEALTHCARE INDUSTRY BY OFFERING RAPID INFECTIOUS DISEASE DIAGNOSTIC SOLUTIONS. BY REDEFINING STANDARDS OF CARE, MELIO AIMS TO DRIVE A SHIFT TOWARD PRECISION HEALTHCARE,… |
| 2025-10-22 | Uh-Oh Labs Inc | $1.25M | THE KEY GOAL OF THIS PROGRAM IS TO DEVELOP A DESIGN-LOCKED VERSION OF STI SCOUT, AN IN VITRO DIAGNOSTIC (IVD) FOR THE DETECTION OF GONORRHEA AND CHLAMYDIA FROM MALE URINE AND FEMALE VAGINAL SWAB SAMPLES. THE TARGET… |
| 2022-11-07 | Macro Biologics, Inc. | $1.24M | INFECTION IS A PROGRESSION, BEST STOPPED EARLY. DANGEROUS MICROBES REACH VULNERABLE TISSUES BY PASSING THROUGH “GATEWAYS”, SUCH AS SURGICAL & TRAUMATIC WOUNDS, THROAT & UPPER AIRWAY, AND URINARY TRACT. A FOCAL… |
| 2023-01-24 | Institute for Life Science Entrepreneurship Inc | $1.07M | THE ACCELERATOR WILL PROVIDE A BROAD RANGE OF SUPPORT TO PRODUCT DEVELOPERS FUNDED BY CARB-X. THIS WILL INCLUDE PROJECT SPECIFIC SUPPORT, SUPPORT ACROSS PROJECTS, AND SUPPORT CULTIVATING THE BROADER COMMUNITY OF PEOPLE… |
| 2022-10-05 | Lumen Bioscience, Inc | $1.07M | DIARRHEAL DISEASES ARE A MAJOR CAUSE OF INFANT MORTALITY AND MORBIDITY IN THE DEVELOPING WORLD, WHERE TWO OF THE MAJOR CAUSAL PATHOGENS ARE CAMPYLOBACTER JEJUNI (C. JEJUNI) AND ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC).… |
| 2025-03-25 | Arrepath Inc | $1.03M | THE OVERALL GOAL OF THIS PROJECT IS TO DEVELOP AN IV + ORAL AGENT WITH A NOVEL MECHANISM OF ACTION (MOA) FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) CAUSED BY MDR ENTEROBACTERALES. ARREPATH HAS… |
| 2024-08-12 | Locus Biosciences Inc | $1.03M | LOCUS BIOSCIENCES IS A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ANTIBACTERIAL THERAPIES USING ENGINEERED BACTERIOPHAGES (CRPHAGE AND DEPOLYMERASE-ENGINEERED), WHICH ARE VIRUSES THAT CAN KILL BACTERIA. THIS… |
| 2026-02-03 | Chembio Diagnostic Systems Inc. | $1.01M | THE OBJECTIVE OF THE PROPOSED PROGRAM IS TO DEVELOP AN ACCURATE RAPID POINT-OF-CARE (POC) TEST FOR IGA ANTIBODY DETECTION IN TYPHOID FEVER USING CHEMBIO PATENTED DUAL PATH PLATFORM (DPP) TECHNOLOGY. IN THE PRESENT… |
| 2025-08-18 | Quantamatrix Incorporated | $998.1K | QMAP (QUICK MULTIPLEXED ASSAY PLATFORM) IS A CHEAP, FAST, ACCURATE, AND HIGHLY SCALABLE FULLY AUTOMATED SYSTEM FOR NEONATAL SEPSIS SCREENING. IT CAN OFFER BROAD-SPECTRUM ANALYSIS OF MOLECULAR MARKERS REPRESENTING… |
7 actions since 2023-03-21. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-04-28 | P00009 | Option exercised | $10.78M | CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA - UPDATE PERIOD OF PERFORMANCE |
| 2025-04-22 | P00008 | Change order | $0 | CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA - UPDATE PERIOD OF PERFORMANCE |
| 2025-03-10 | P00007 | Option exercised | $33.00M | CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA - EXERCISE OPTION 3 |
| 2024-04-08 | P00006 | Option exercised | $22.00M | CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA |
| 2024-02-21 | P00005 | Change order | $0 | CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA - ADD FUNDS |
| 2023-09-06 | P00004 | Supplemental agreement (work within scope) | $20.00M | CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA - ADD FUNDS |
| 2023-03-21 | P00003 | Option exercised | $40.00M | CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-20). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗